2023 ISAKOS Biennial Congress In-Person Poster
Favorable Outcomes Following Extracorporeal Shockwave Therapy for Chronic Non-Insertional Achilles Tendinopathy compared to Insertional Achilles Tendinopathy: A Retrospective Review
James J Butler, MB BCh, New York, New York UNITED STATES
Mohammad T Azam, BS UNITED STATES
Brittany DeClouette, MD, New York, New York UNITED STATES
Cian Walls, New York, New York UNITED STATES
George Jejelava, BS, New York, New York UNITED STATES
Danny Zheng, MD, New York, NEW YORK UNITED STATES
John G. Kennedy, MD, FRCS, New York, NY UNITED STATES
New York University Langone Health, New York, New York, UNITED STATES
FDA Status Not Applicable
Summary
The clinical benefit following ESWT is sustained in the NAT cohort but deteriorates in the IAT cohort, suggesting that ESWT is a temporising treatment strategy for patients with IAT.
Abstract
Background
Extracorporeal shockwave therapy (ESWT) is a non-invasive treatment modality that is utilized in the treatment of chronic Achilles tendinopathy (AT).
Purpose
The purpose of this study was to retrospectively assess outcomes following ESWT for both NAT and IAT at greater than 1-year follow-up, and to identify potential predictors of outcomes.
Study design: Retrospective case series
Methods
Chart review was conducted to identify patients who underwent ESWT for AT with a minimum of 1-year follow-up. Data collected and assessed included: patient demographics, pathological characteristics, treatment characteristics, Victorian Institute of Sports Assessment-Achilles (VISA-A) and visual analog scale (VAS) scores and failures. Linear regression was performed to identify potential predictors of outcomes. Survival analysis was conducted using Kaplan Meier curves.
Results
Fifty-two cases of IAT and 34 cases of NAT were included. The mean follow-up in the NAT cohort was 22.3±10.2 months and the mean follow-up time in the IAT cohort was 26.8±15.8 months. Improvements in VISA-A and VAS scores were observed in the NAT cohort at 6 months follow-up and at final follow-up (p<0.01). Improvements in VISA-A scores and VAS scores were recorded in the IAT cohort at 6 months follow-up which subsequently deteriorated at final follow-up. In the NAT cohort, the failure rate at 6 months follow-up was 11.8% which increased to 29.4% at final follow-up. In the IAT cohort, the failure rate at 6 months follow-up was 32.7% which increased to 59.6% at final follow-up. Predictors of poor outcomes in the NAT cohort included pre-ESWT subjective clinical score, male sex, presence of a cardiovascular risk factor, and increasing MRI grading of tendinopathy. Predictors of poor outcomes in the IAT cohort included pre-ESWT subjective clinical score and increasing MRI grading of tendinopathy.
Conclusion
This study found that superior subjective clinical outcomes together with a lower failure rate maintained over 1 year in the NAT cohort compared to the IAT cohort. This may implicate ESWT as a temporising treatment in IAT and a longer term solution in patients with NAT.